Nyumbani › Mesothelioma › Virginia
Majaribio ya kliniki ya Mesothelioma katika jimbo la Virginia
Masomo 8 ya Mesothelioma yanatafuta washiriki katika vituo vya jimbo la Virginia.
Miji katika jimbo la Virginia
Maandishi rasmi ya utafiti (Kiingereza)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- NEXT Oncology Virginia, Fairfax
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 28 Sep 2026 · NCT07277413Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Next Oncology Virginia, Fairfax
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 8 Sep 2026 · NCT05732831Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Virginia Cancer Specialists, PC, Fairfax
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 2 Sep 2026 · NCT05245500A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT04104776Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 4 Ago 2026 · NCT05579366A 2-part Phase 1/2 Open-label Trial on ODM-212
- NEXT Oncology Virginia, Fairfax
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 4 Mei 2026 · NCT07563738Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- Virginia Cancer Specialists, PC, Arlington
InaajiriHatua 1/2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 2 Apr 2026 · NCT04665206A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 9 Sep 2025 · NCT05107674Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.